Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Choroidal Neovascularization
Conditions
Choroidal Neovascularization
Trial Timeline
Dec 5, 2014 → Aug 22, 2018
NCT ID
NCT02260687About Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) is a pre-clinical stage product being developed by Regeneron Pharmaceuticals for Choroidal Neovascularization. The current trial status is completed. This product is registered under clinical trial identifier NCT02260687. Target conditions include Choroidal Neovascularization.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02811692 | Pre-clinical | Completed |
| NCT02924311 | Pre-clinical | Completed |
| NCT02540369 | Pre-clinical | Completed |
| NCT02541084 | Pre-clinical | Completed |
| NCT02305238 | Approved | Completed |
| NCT02260687 | Pre-clinical | Completed |
| NCT02120950 | Approved | Completed |
| NCT01783925 | Pre-clinical | Completed |
| NCT02040220 | Pre-clinical | Completed |
| NCT02279537 | Pre-clinical | Completed |
| NCT01914380 | Pre-clinical | Completed |
| NCT01756261 | Pre-clinical | Completed |
Competing Products
20 competing products in Choroidal Neovascularization
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zimura + Eylea | Astellas Pharma | Phase 2 | 52 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2 | 52 |
| Verteporfin Photodynamic Therapy + Ranibizumab | Novartis | Approved | 85 |
| ranibizumab | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |
| ranibizumab | Novartis | Phase 3 | 77 |
| Everolimus + Ranibizumab | Novartis | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| ranibizumab 0.5mg | Novartis | Phase 2 | 52 |
| ranibizumab | Novartis | Phase 3 | 77 |
| Brolucizumab 6mg + Brolucizumab 6mg | Novartis | Phase 3 | 77 |
| Intravitreal injection ranibizumab | Novartis | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Phase 1/2 | 41 |
| Faricimab + Ranibizumab + Sham Procedure | Roche | Phase 2 | 52 |
| Faricimab + Ranibizumab | Roche | Phase 3 | 77 |
| Faricimab + Ranibizumab + Sham Procedure | Roche | Phase 2 | 52 |
| Intravitreal Pegaptanib | Pfizer | Pre-clinical | 22 |
| Intravitreal aflibercept injection 2.0mg | Regeneron Pharmaceuticals | Approved | 84 |